rais po follow strong
report new po base ep
previous think mdt next quarter report novemb less like
catalyst given tougher comp mdt higher stock price better growth
back half fiscal year solid pipeline/outlook fiscal earn power
rang calendar suggest us new po
achiev within month updat model reflect result
next big event septemb robot analyst day
comment call yesterday suggest us approv robot
come earlier street expect consensu model littl noth mdt
robot fiscal fiscal therefor think would see much
downsid say us robot launch remain month
away us approv timelin would within month analyst day
meaning posit view year wait us approv would
disappoint view would chang model
would impact basi point
regard said ischem stroke growth includ stent retriev
aspir cathet mid high consist growth around
world also state us aspir market share quarter high
teen mid-teen last quarter faster growth rate
report hesit read much comment two compani
geographi get univers strong feedback
doctor pen new cathet think help pen calendar result
regard view mdt lack commentari us timelin small posit
near term regard state us approv next
gener recharg urinari incontin devic year batteri life could
happen earli fiscal spring calendar timelin hit would
leav roughli month window launch mdt launch
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
medic devic compani
oper four busi segment cardiac
diabet group minim invas therapi
buy rate continu believ
cov deal lower risk profil
better posit win new healthcar
environ longer term exposur
major med-tech growth market see
enough pipelin deliv
revenu growth ep growth go
major restructur near term would
increas investor expect leverag
price object base trade ep
slight discount peer approx think small discount group
warrant given recent execut misstep sever revenu headwind
upsid risk price object greater-than-expect revenu growth new
product robot develop market share gain competit product delay
acceler end-market growth downsid risk price object
competit share loss and/or price pressur
bob hopkin herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
becton dickinson compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
